Matica Continuing In The Medical Marijuana Field

November 17, 2016 – Toronto, Ontario – Matica Enterprises Inc. (MMJ–CSE) (39N – Frankfurt) (MQPXF – OTC PINK) (“Matica” or the “Company”) is pleased to report that the Company is actively reviewing medical marijuana facilities with an intent to continue in the medical marijuana field.  Over the past week Matica management reviewed several locations including a tour of a facility of a late stage applicant in south-western Ontario. The facility has an application pending under the Marijuana for Medical Purposes Regulation (“MMPR”) program.

Matica management and consultants will be conducting reviews of several facilities.  The ultimate goal of any ensuing transaction is for Matica to become a majority owner and operator of a Licenced Producer under the Access To Cannabis for Medical Purposes Regulation (“ACMPR”).

 

For more information on Matica please visit the website at: www.westislandbrands.com.

 

On behalf of the Board of Directors

MATICA ENTERPRISES INC.

 

Boris Ziger, CEO & Chairman

 

The Company’s filings are available for review at www.sedar.com and www.thecse.com.

For further information, please contact Boris Ziger, Chief Executive Officer, at:

Telephone: 416-304-9935

E-mail: info@westislandbrands.com

Website: www.westislandbrands.com

 

Certain information in this press release may constitute forward-looking information. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Corporation assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward looking-statements unless and until required by securities laws applicable to the Corporation. Additional information identifying risks and uncertainties is contained in the Corporation’s filings with the Canadian securities regulators, which filings are available at www.sedar.com.

The CSE has not reviewed, approved or disapproved the content of this press release.